adenine has been researched along with Acute Myelogenous Leukemia in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose." | 9.07 | Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991) |
| "We have investigated the correlation of clinical responses (decreases of white blood cells and peripheral blasts) with pharmacokinetic and pharmacodynamic parameters in patients with acute myelogenous leukemia who are receiving amonafide." | 7.68 | The correlation of response with plasma pharmacokinetics and polyamine concentrations in patients with acute myelogenous leukemia receiving amonafide. ( Benvenuto, JA; Johnston, DA; Nishioka, K, 1993) |
| "After Phase I studies of benzisoquinolinedione (amonafide) in solid tumors identified myelosuppression as the dose-limiting toxicity, we conducted a Phase I study in patients with relapsed or refractory acute leukemia to define the optimal dose." | 5.07 | Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. ( Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S, 1991) |
| " A 46-year-old female patient with chronic hepatitis B had persistent detectable HBV DNA and positive serum hepatitis B e antigen (HBeAg), even while on long-term lamivudine and adefovir therapy." | 3.77 | Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B. ( Chen, CH; Chiang, LT; Ko, BS; Yao, M, 2011) |
| "We have investigated the correlation of clinical responses (decreases of white blood cells and peripheral blasts) with pharmacokinetic and pharmacodynamic parameters in patients with acute myelogenous leukemia who are receiving amonafide." | 3.68 | The correlation of response with plasma pharmacokinetics and polyamine concentrations in patients with acute myelogenous leukemia receiving amonafide. ( Benvenuto, JA; Johnston, DA; Nishioka, K, 1993) |
| "Ibrutinib alone or in combination with cytarabine or azacitidine demonstrated an acceptable safety profile." | 2.90 | Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. ( Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS, 2019) |
| "Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplastic syndrome or after antineoplastic therapy, responds poorly to current therapies." | 2.80 | Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. ( Allen, SL; Damon, L; Egyed, M; Erba, HP; Horst, HA; Jang, JH; Lundberg, AS; Masszi, T; Mazzola, E; Neuberg, D; Pigneux, A; Powell, B; Rizzieri, D; Sekeres, MA; Selleslag, D; Solomon, SR; Stone, RM; Stuart, RK; Tallman, MS; Venugopal, P; Warzocha, K; Wetzler, M, 2015) |
| " 43 patients with relapsed/refractory or secondary AML or CML blast crisis were enrolled into two phase I dose-escalation studies investigating amonafide as monotherapy or in combination with cytarabine." | 2.75 | Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. ( Allen, SL; Bennett, JM; Budman, DR; Capizzi, RL; Kolitz, JE; Lundberg, AS, 2010) |
| "Amonafide is a novel topoisomerase II (Topo II) inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA." | 2.47 | Amonafide: a potential role in treating acute myeloid leukemia. ( Allen, SL; Lundberg, AS, 2011) |
| "Cotylenin A has been isolated as a plant growth regulator exhibits cytokinin-like activity." | 2.41 | Differentiation of human myeloid leukemia cells by plant redifferentiation-inducing hormones. ( Honma, Y; Ishii, Y, 2002) |
| "Do patients with therapy-related acute myeloid leukemia (t-AML) have a poor prognosis independent of other predictive variables such as cytogenetics or molecular determinants? Limited data exist to answer this question in part because t-AML is often considered together with AML following myelodysplastic syndromes (MDS) in the category of secondary AML." | 1.37 | Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants? ( Feldman, EJ, 2011) |
| " IC87114 did not have direct adverse effects or enhance the activity of VP16 on the proliferation and survival of normal haemopoietic progenitors." | 1.33 | A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. ( Billottet, C; Gale, RE; Grandage, VL; Khwaja, A; Quattropani, A; Rommel, C; Vanhaesebroeck, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (19.51) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 4 (9.76) | 29.6817 |
| 2010's | 23 (56.10) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Perrard, N | 1 |
| Pokeerbux, MR | 1 |
| Quesnel, B | 1 |
| Duployez, N | 1 |
| Fenwarth, L | 1 |
| Preudhomme, C | 1 |
| Lefèvre, G | 1 |
| Baillet, C | 1 |
| Launay, D | 1 |
| Terriou, L | 1 |
| Eide, CA | 1 |
| Kurtz, SE | 1 |
| Kaempf, A | 1 |
| Long, N | 1 |
| Agarwal, A | 1 |
| Tognon, CE | 1 |
| Mori, M | 1 |
| Druker, BJ | 1 |
| Chang, BH | 1 |
| Danilov, AV | 1 |
| Tyner, JW | 1 |
| Huls, G | 1 |
| Chitu, DA | 1 |
| Pabst, T | 1 |
| Klein, SK | 1 |
| Stussi, G | 1 |
| Griskevicius, L | 1 |
| Valk, PJM | 1 |
| Cloos, J | 1 |
| van de Loosdrecht, AA | 1 |
| Breems, D | 1 |
| van Lammeren-Venema, D | 1 |
| van Zeventer, I | 1 |
| Boersma, R | 1 |
| Jongen-Lavrencic, M | 1 |
| Fehr, M | 1 |
| Hoogendoorn, M | 1 |
| Manz, MG | 1 |
| Söhne, M | 1 |
| van Marwijk Kooy, R | 1 |
| Deeren, D | 1 |
| van der Poel, MWM | 1 |
| Legdeur, MC | 1 |
| Tick, L | 1 |
| Chalandon, Y | 1 |
| Ammatuna, E | 1 |
| Blum, S | 1 |
| Löwenberg, B | 1 |
| Ossenkoppele, GJ | 1 |
| Carlos, JAEG | 1 |
| Lima, K | 1 |
| Costa-Lotufo, LV | 1 |
| Leitão, A | 1 |
| Machado-Neto, JA | 1 |
| Xie, C | 1 |
| He, Y | 1 |
| Zhen, M | 1 |
| Wang, Y | 1 |
| Xu, Y | 1 |
| Lou, L | 1 |
| Snijder, B | 1 |
| Vladimer, GI | 1 |
| Krall, N | 1 |
| Miura, K | 1 |
| Schmolke, AS | 1 |
| Kornauth, C | 1 |
| Lopez de la Fuente, O | 1 |
| Choi, HS | 1 |
| van der Kouwe, E | 1 |
| Gültekin, S | 1 |
| Kazianka, L | 1 |
| Bigenzahn, JW | 1 |
| Hoermann, G | 1 |
| Prutsch, N | 1 |
| Merkel, O | 1 |
| Ringler, A | 1 |
| Sabler, M | 1 |
| Jeryczynski, G | 1 |
| Mayerhoefer, ME | 1 |
| Simonitsch-Klupp, I | 1 |
| Ocko, K | 1 |
| Felberbauer, F | 1 |
| Müllauer, L | 1 |
| Prager, GW | 1 |
| Korkmaz, B | 1 |
| Kenner, L | 1 |
| Sperr, WR | 1 |
| Kralovics, R | 1 |
| Gisslinger, H | 1 |
| Valent, P | 1 |
| Kubicek, S | 1 |
| Jäger, U | 1 |
| Staber, PB | 1 |
| Superti-Furga, G | 1 |
| Dwivedi, P | 1 |
| Muench, DE | 1 |
| Wagner, M | 1 |
| Azam, M | 1 |
| Grimes, HL | 1 |
| Greis, KD | 1 |
| Khoury, H | 1 |
| He, R | 1 |
| Schimmer, A | 1 |
| Beadle, JR | 1 |
| Hostetler, KY | 1 |
| Minden, MD | 3 |
| Cortes, JE | 1 |
| Jonas, BA | 1 |
| Graef, T | 1 |
| Luan, Y | 1 |
| Stein, AS | 1 |
| Reikvam, H | 1 |
| Nepstad, I | 1 |
| Bruserud, Ø | 1 |
| Hatfield, KJ | 1 |
| Rushworth, SA | 4 |
| Murray, MY | 3 |
| Zaitseva, L | 4 |
| Bowles, KM | 4 |
| MacEwan, DJ | 4 |
| Davids, MS | 1 |
| Pabst, C | 1 |
| Krosl, J | 1 |
| Fares, I | 1 |
| Boucher, G | 1 |
| Ruel, R | 1 |
| Marinier, A | 1 |
| Lemieux, S | 1 |
| Hébert, J | 1 |
| Sauvageau, G | 1 |
| Shafat, MS | 2 |
| Lawes, MJ | 2 |
| Stone, RM | 2 |
| Mazzola, E | 1 |
| Neuberg, D | 1 |
| Allen, SL | 3 |
| Pigneux, A | 1 |
| Stuart, RK | 1 |
| Wetzler, M | 1 |
| Rizzieri, D | 1 |
| Erba, HP | 1 |
| Damon, L | 1 |
| Jang, JH | 1 |
| Tallman, MS | 1 |
| Warzocha, K | 1 |
| Masszi, T | 1 |
| Sekeres, MA | 1 |
| Egyed, M | 1 |
| Horst, HA | 1 |
| Selleslag, D | 1 |
| Solomon, SR | 1 |
| Venugopal, P | 1 |
| Lundberg, AS | 3 |
| Powell, B | 1 |
| Wu, H | 1 |
| Hu, C | 1 |
| Wang, A | 1 |
| Weisberg, EL | 1 |
| Wang, W | 1 |
| Chen, C | 1 |
| Zhao, Z | 1 |
| Yu, K | 1 |
| Liu, J | 2 |
| Wu, J | 1 |
| Nonami, A | 1 |
| Wang, L | 1 |
| Wang, B | 1 |
| Liu, S | 1 |
| Griffin, JD | 1 |
| Liu, Q | 1 |
| Pillinger, G | 2 |
| Abdul-Aziz, A | 2 |
| Lawes, M | 1 |
| Rotin, LE | 2 |
| Gronda, M | 2 |
| MacLean, N | 1 |
| Hurren, R | 2 |
| Wang, X | 2 |
| Lin, FH | 1 |
| Wrana, J | 1 |
| Datti, A | 1 |
| Barber, DL | 1 |
| Slassi, M | 2 |
| Schimmer, AD | 2 |
| Piddock, R | 1 |
| Smith, LL | 1 |
| Li, X | 1 |
| Yin, X | 1 |
| Wang, H | 1 |
| Huang, J | 1 |
| Yu, M | 1 |
| Ma, Z | 1 |
| Li, C | 1 |
| Zhou, Y | 1 |
| Yan, X | 1 |
| Huang, S | 1 |
| Jin, J | 1 |
| Tallman, M | 1 |
| Kolitz, JE | 1 |
| Bennett, JM | 1 |
| Capizzi, RL | 1 |
| Budman, DR | 1 |
| Chiang, LT | 1 |
| Yao, M | 1 |
| Ko, BS | 1 |
| Chen, CH | 1 |
| Feldman, EJ | 1 |
| Freeman, CL | 1 |
| Swords, R | 1 |
| Giles, FJ | 1 |
| Honma, Y | 1 |
| Ishii, Y | 1 |
| Fouillard, L | 1 |
| Serfaty, L | 1 |
| Gozlan, J | 1 |
| Billottet, C | 1 |
| Grandage, VL | 1 |
| Gale, RE | 1 |
| Quattropani, A | 1 |
| Rommel, C | 1 |
| Vanhaesebroeck, B | 1 |
| Khwaja, A | 1 |
| King, ME | 1 |
| Honeysett, JM | 1 |
| Howell, SB | 1 |
| Benvenuto, JA | 2 |
| Johnston, DA | 1 |
| Nishioka, K | 1 |
| O'Brien, S | 1 |
| Estey, E | 1 |
| Beran, M | 2 |
| Felder, TB | 1 |
| Keating, M | 1 |
| Weber, G | 1 |
| Jayaram, HN | 1 |
| Lapis, E | 1 |
| Natsumeda, Y | 1 |
| Yamada, Y | 1 |
| Yamaji, Y | 1 |
| Tricot, GJ | 1 |
| Hoffman, R | 1 |
| Andersson, BS | 1 |
| Bakic, M | 1 |
| Silberman, LE | 1 |
| Newman, RA | 1 |
| Zwelling, LA | 1 |
| Rosman, M | 1 |
| Williams, HE | 1 |
| Fields, T | 1 |
| Brox, L | 1 |
| Wilmanns, W | 1 |
| Smith, JL | 1 |
| Omura, GA | 1 |
| Krakoff, IH | 1 |
| Balis, ME | 1 |
| Shirakawa, S | 1 |
| Saunders, GF | 1 |
| Griffin, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology[NCT04470947] | 150 participants (Anticipated) | Observational [Patient Registry] | 2020-06-10 | Recruiting | |||
| Pharmacoscopy-guided Clinical Standard-of-care in Relapsed/Refractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial[NCT06138990] | 82 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients[NCT03096821] | 143 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study[NCT00715637] | Phase 3 | 420 participants (Anticipated) | Interventional | 2007-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for adenine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Amonafide: a potential role in treating acute myeloid leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Clinical Trials as Topic; DNA Topoisomerases, Type II; Drug | 2011 |
Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Leukemia, Myeloid, Acute; | 2012 |
Differentiation of human myeloid leukemia cells by plant redifferentiation-inducing hormones.
Topics: Adenine; Antioxidants; Cell Differentiation; Cell Line, Tumor; Cytokinins; Diterpenes; Dose-Response | 2002 |
6 trials available for adenine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Topics: Adenine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Netherlands; Piper | 2020 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; | 2017 |
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohor | 2019 |
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2015 |
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2010 |
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evalu | 1991 |
32 other studies available for adenine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
[GATA2 gene mutations: 3 cases].
Topics: Adenine; Adult; Female; GATA2 Transcription Factor; Humans; Immunologic Deficiency Syndromes; Leukem | 2022 |
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heteroc | 2020 |
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cell Su | 2021 |
Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
Topics: Adenine; Aminoquinolines; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Cla | 2017 |
Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Proliferation; Cell Transformation, Neop | 2019 |
Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Topics: Adenine; Animals; Apoptosis; Caspases; Cell Cycle Checkpoints; Cytarabine; DNA Damage; Drug Compound | 2018 |
Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cytogenetics; Cytokines; Female; Humans; | 2013 |
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Apoptosis; Cell Adhesi | 2014 |
Boldly Targeting Kinases without mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Female; Humans; Leukemia, Lymphocytic, Chroni | 2014 |
Identification of small molecules that support human leukemia stem cell activity ex vivo.
Topics: Adenine; Cell Culture Techniques; Culture Media, Serum-Free; Drug Screening Assays, Antitumor; Human | 2014 |
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Cell Line, Tumor; Cell | 2014 |
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Benzamides; Bridged | 2016 |
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blast Crisis; Cell Line, Tumor; Cell Surviv | 2015 |
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; | 2016 |
Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; B-Lymphocytes; Female; | 2015 |
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
Topics: Adenine; Cytarabine; Daunorubicin; Leukemia, Myeloid, Acute; Piperidines; Pyrazoles; Pyrimidines | 2016 |
58th American Society of Hematology Annual Meeting.
Topics: ADAMTS13 Protein; Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Central Venous Catheters; | 2017 |
The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tu | 2017 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2008 |
Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B.
Topics: Adenine; Adoptive Transfer; Antiviral Agents; DNA, Viral; Drug Combinations; Female; Hepatitis B Ant | 2011 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; | 2011 |
Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation.
Topics: Adenine; Adult; Antineoplastic Agents; Combined Modality Therapy; Female; Hepatitis B; Hepatitis B v | 2006 |
A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
Topics: Adenine; Apoptosis; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug | 2006 |
Regulation of de novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine.
Topics: Adenine; Bone Marrow; Bone Marrow Cells; DNA; Guanine; Humans; Hypoxanthine; Hypoxanthines; Leukemia | 1983 |
The correlation of response with plasma pharmacokinetics and polyamine concentrations in patients with acute myelogenous leukemia receiving amonafide.
Topics: Adenine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Half-Life; Humans; Imides; Iso | 1993 |
Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Topics: Adenine; Aged; Allopurinol; Animals; Drug Evaluation; Female; Guanine; Guanosine Triphosphate; Human | 1988 |
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia.
Topics: Adenine; Amsacrine; Cell Line; Clone Cells; DNA; DNA Topoisomerases, Type I; Doxorubicin; Electropho | 1987 |
Leukocyte purine phosphoribosyltransferases in human leukemias sensitive and resistant to 6-thiopurines.
Topics: Adenine; Adolescent; Adult; Aged; Antimetabolites; Drug Resistance; Female; Guanine; Humans; Hypoxan | 1973 |
Purine and pyrimidine pool sizes and purine base utilization in human lymphocytes and cultured lymphoblasts.
Topics: Adenine; Adenine Nucleotides; Burkitt Lymphoma; Carbon Radioisotopes; Cell Line; Centrifugation, Den | 1974 |
Synthesis of purine nucleotides in human and leukemic cells. Interaction of 6-mercaptopurine and allopurinol.
Topics: Adenine; Allopurinol; Bone Marrow; Bone Marrow Cells; Carbon Radioisotopes; Cell-Free System; Chroma | 1973 |
IMP: and AMP:pyrophosphate phosphoribosyltransferase in leukemic and normal human leukocytes.
Topics: Adenine; Carbon Isotopes; Erythrocytes; Guanine; Humans; Hypoxanthines; In Vitro Techniques; Leukemi | 1971 |
In vivo methylation of DNA in human leukocytes.
Topics: Adenine; Cytosine; DNA; Guanine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; M | 1971 |